Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 25 Novo Nordisk has leading positions in diabetes, haemophilia and growth disorders Diabetes Haemophilia Growth disorders DKK billion Market value DKK Market value DKK Market value Novo Nordisk value market share billion Global market position Novo Nordisk value market share Global market position billion Novo Nordisk value market share Global market position 500 50% 70 40% 30 40% #1 #2 #1 60 400 - 40% - 30% - 30% 50 20 300 30% 40 20% 20% 30 200 CAGR¹ value: 17.4% 100 20% 10 20 CAGR¹ value: 4.6% CAGR¹ value: 1.8% 10% 10% . 10% 10 0 Aug 2011 0% 0 Aug 2016 FY 2011 0% FY 2015 1 CAGR for 5-year period Source: IMS MAT August, 2016 value figures Note: Annual sales figures for Haemophilia A, B and inhibitor segment 1 CAGR for 5-year period Source: Company reports Aug 2011 1 CAGR for 5-year period 0% Aug 2016 Source: IMS MAT August, 2016 value figures changing diabetes novo nordisk

View entire presentation